Zepp Health FY26 Q2 net loss widens to US$11.3 million; revenue rises 6.9% to US$63.5 million

• Zepp posted Q2 2026 revenue of US$63.5 million, up 6.9% from a year earlier.
• Net loss attributable to shareholders widened to US$11.3 million; loss per ADS deepened to US$0.72 on a GAAP basis.
• Gross margin rose to 37.4%, up 1.2 percentage points year over year, driven by a more favorable product mix.
• Cash, cash equivalents, restricted cash totaled US$106.3 million at June 30, 2026, reflecting improved working-capital management.
• Guided Q3 2026 revenue at US$68 million to US$73 million; plans Bip family price increases starting January 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zepp Health Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609012100PR_NEWS_USPR_____CN38215) on September 02, 2026, and is solely responsible for the information contained therein.